Tesamorelin
Tesamorelin is a GHRH analog that is FDA-approved as Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy. It is a prescription drug for that specific use.
What it is
A stabilized version of growth-hormone-releasing hormone.
What the evidence shows
In people
Randomized trials in people with HIV-associated lipodystrophy showed reductions in visceral abdominal fat. Results do not automatically apply to other groups.
In animals and labs
Supporting mechanism work.
Legal status
Approved as Egrifta for one indication. Research-grade tesamorelin is not that product. Prohibited in sport.
Dosing
Dosing is set by the label and your prescriber
Doses for approved products come from the FDA-approved label and are adjusted by a prescriber for each person. BOTH does not restate dosing. Read the official label below and ask your prescriber or pharmacist how to measure and take your dose.
- Egrifta · HIV-associated abdominal fatOfficial label on DailyMed ↗
Known risks
- Joint pain, swelling, and injection-site reactions
- Raised blood sugar
- Not for use in pregnancy